Cryoport to Report Second Quarter 2024 Financial Results on August 6, 2024
Cryoport (Nasdaq: CYRX), a global leader in life sciences supply chain solutions, has announced it will report its second quarter 2024 financial results on August 6, 2024, after U.S. markets close. The company will release a document titled 'Cryoport Second Quarter 2024 in Review' at 4:05 p.m. ET, providing a comprehensive review of financial and operational performance, along with a general business update.
A conference call will be held the same day at 5:00 p.m. ET, featuring a Q&A session with management addressing questions from the investment community. The call will be accompanied by a slide deck and can be accessed via phone or webcast. A recording of the call will be available on the company's website for a time, with a dial-in replay accessible until August 13, 2024.
Cryoport (Nasdaq: CYRX), un leader globale nelle soluzioni della catena di approvvigionamento per le scienze della vita, ha annunciato che riporterà i risultati finanziari del secondo trimestre 2024 il 6 agosto 2024, dopo la chiusura dei mercati americani. L'azienda rilascerà un documento intitolato 'Ripasso del Secondo Trimestre 2024 di Cryoport' alle 16:05 ET, fornendo una panoramica completa delle performance finanziarie e operative, insieme a un aggiornamento generale sull'azienda.
Un conference call si terrà lo stesso giorno alle 17:00 ET, con una sessione di domande e risposte con la direzione che affronterà le domande della comunità degli investitori. La chiamata sarà accompagnata da un insieme di diapositive e può essere accessibile tramite telefono o webcast. Una registrazione della chiamata sarà disponibile sul sito web dell’azienda per un periodo di tempo, con un replay accessibile fino al 13 agosto 2024.
Cryoport (Nasdaq: CYRX), un líder mundial en soluciones de cadena de suministro para ciencias de la vida, ha anunciado que reportará sus resultados financieros del segundo trimestre de 2024 el 6 de agosto de 2024, después del cierre de los mercados estadounidenses. La compañía publicará un documento titulado 'Cryoport Segundo Trimestre 2024 en Revisión' a las 4:05 p.m. ET, proporcionando una revisión integral del desempeño financiero y operativo, junto con una actualización general del negocio.
Una conferencia telefónica se llevará a cabo el mismo día a las 5:00 p.m. ET, con una sesión de preguntas y respuestas con la gerencia que abordará preguntas de la comunidad inversora. La llamada será acompañada por una presentación y se podrá acceder por teléfono o webcast. Una grabación de la llamada estará disponible en el sitio web de la empresa por un tiempo, con un acceso de repetición hasta el 13 de agosto de 2024.
Cryoport (Nasdaq: CYRX), 생명과학 공급망 솔루션의 글로벌 리더가 2024년 2분기 재무 결과를 2024년 8월 6일 미국 시장 마감 후 보고할 계획이라고 발표했습니다. 회사는 오후 4시 5분 ET에 'Cryoport 2024년 2분기 검토'라는 제목의 문서를 발표하여 재무 및 운영 성과에 대한 포괄적인 검토와 일반적인 사업 업데이트를 제공합니다.
같은 날 오후 5시 ET에 컨퍼런스 콜이 진행되며, 경영진과의 질의응답 시간이 포함되어 투자자 커뮤니티의 질문에 답변합니다. 이 전화 회의는 슬라이드 자료와 함께 진행되며 전화 또는 웹 캐스트를 통해 접근할 수 있습니다. 전화 회의 녹음은 회사 웹사이트에서 일정 기간 동안 이용할 수 있으며, 2024년 8월 13일까지 재접속할 수 있습니다.
Cryoport (Nasdaq: CYRX), un leader mondial des solutions de chaîne d'approvisionnement en sciences de la vie, a annoncé qu'il publiera ses résultats financiers du deuxième trimestre 2024 le 6 août 2024, après la fermeture des marchés américains. L'entreprise publiera un document intitulé 'Revue du Deuxième Trimestre 2024 de Cryoport' à 16h05 ET, fournissant une revue complète des performances financières et opérationnelles, ainsi qu'une mise à jour générale sur l'entreprise.
Un appel conférence sera tenu le même jour à 17h00 ET, avec une session de questions-réponses avec la direction répondant aux questions de la communauté des investisseurs. L'appel sera accompagné d'une présentation et pourra être accessible par téléphone ou webinaire. Un enregistrement de l'appel sera disponible sur le site web de l'entreprise pendant un certain temps, avec un accès à la rediffusion jusqu'au 13 août 2024.
Cryoport (Nasdaq: CYRX), ein weltweit führendes Unternehmen im Bereich Lösungen für die Lieferkette der Lebenswissenschaften, hat bekannt gegeben, dass es seine Finanzergebnisse für das zweite Quartal 2024 am 6. August 2024 nach Börsenschluss in den USA berichten wird. Das Unternehmen wird um 16:05 Uhr ET ein Dokument mit dem Titel 'Cryoport Rückblick auf das zweite Quartal 2024' veröffentlichen, das eine umfassende Übersicht über die finanzielle und operative Leistung sowie ein allgemeines Update zum Geschäft bietet.
Am selben Tag um 17:00 Uhr ET wird eine Telefonkonferenz stattfinden, in der das Management Fragen aus der Investoren-Community beantworten wird. Die Konferenz wird von einer Präsentation begleitet und kann über Telefon oder Webcast erreicht werden. Eine Aufnahme der Konferenz wird für eine Zeit auf der Unternehmenswebsite verfügbar sein, mit einem Zugriff auf die Wiederholung bis zum 13. August 2024.
- None.
- None.
In addition to the earnings release, a document titled "Cryoport Second Quarter 2024 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Tuesday, August 6, 2024. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.
Cryoport management will host a conference call the same day at 5:00 p.m. ET. The conference call will be in the format of a questions and answers session and will address questions members of the investment community have regarding the Company's reported results. A slide deck will accompany the call.
Conference Call Information
Date: | Tuesday, August 6, 2024 |
Time: | 5:00 p.m. ET |
Dial-in numbers: | 1-800-717-1738 ( |
Confirmation code: | Request the "Cryoport Call" or Conference ID: 1157932 |
Live webcast: | 'Investor Relations' section at www.cryoportinc.com or click here.
Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software. |
The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until August 13, 2024. To access the replay, dial 1-844-512-2921 (
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for cell & gene therapies that enable manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Its corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as Cryoport's outlook and guidance for full year 2024 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Cryoport operates, Cryoport's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, Cryoport's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of Cryoport's clients. Forward-looking statements also include those related to Cryoport's anticipation that its revenue will progressively improve throughout the year, including anticipated acceleration of revenue from Cryoport's Cell & Gene Therapy clients, Cryoport's expectations that cryogenic systems product sales will be challenging throughout the remainder of the year, Cryoport's expectations of the long-term prospects of its Life Sciences Products business, including the anticipation of demand normalizing, which would allow Cryoport to benefit from its position as the global leader in this space, and Cryoport's planned initiatives to drive toward positive adjusted EBITDA and cash flow in the near term, which it expects should positively impact its results of operations for the second half of 2024. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-second-quarter-2024-financial-results-on-august-6-2024-302203587.html
SOURCE Cryoport, Inc.
FAQ
When will Cryoport (CYRX) report its Q2 2024 financial results?
What time is Cryoport's (CYRX) Q2 2024 earnings conference call?
How can investors access Cryoport's (CYRX) Q2 2024 earnings call?
Will Cryoport (CYRX) provide additional materials for the Q2 2024 earnings release?
